Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA analysis system to conventional gel based systems for HIV drug resistance analysis

Journal of Virological Methods

Volumn 98, Issue 1, 2001, Pages 9-16

  Merel, Patrick ^a,b   Pellegrin, Isabelle ^a   Garrigue, Isabele ^a   Caumont, Anne ^a   Schrive, Marie Hélène ^a   Birac, Valérie ^a   Bonot, Pascal ^a   Fleury, Hervé ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Capillary electrophoresis; Cost effectiveness; HIV 1 genotyping; Sequencing

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ERROR; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; ELECTROPHORESIS, CAPILLARY; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REAGENT KITS, DIAGNOSTIC; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034838469     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(01)00338-X     Document Type: Article

References (14)

1. Final results of CPCRA 046: A pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
2. Differences in protease and reverse transcriptase sequences between the TruGene HIV-1 genotyping kit (Visible Genetics) and the ViroSeq genotyping system (PE Applied Biosystem)
3. Correlation of baseline phenotypic drug susceptibility with 16 weeks virologic response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy
4. Novel four-drug salvage treatment regimens after failure of human immunodeficiency virus type 1 protease inhibitor-containing regimen
5. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
6. Baseline resistance profile predicts response to SQV/RTV therapy in a community setting
7. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA panel
8. A blinded comparison of two sequencing assays for resistance mutations in HIV-1 protease and reverse transcriptase genes in the GART study (CPCRA 046)
9. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592)
10. Impact of drug resistance mutations on virologic response to salvage therapy
11. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the HIV-1 reverse transcriptase
12. Budget impact of the integration of genotypic antiretroviral resistance testing into HIV treatment guides
13. Comparative evaluation of three human immunodeficiency virus genotyping systems: The HIV-GenotypR method, the HIV PRT GeneChip Assay, and the HIV-1 RT Line Probe Assay
14. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitors therapy had failed